JP2023550485A5 - - Google Patents

Info

Publication number
JP2023550485A5
JP2023550485A5 JP2023530843A JP2023530843A JP2023550485A5 JP 2023550485 A5 JP2023550485 A5 JP 2023550485A5 JP 2023530843 A JP2023530843 A JP 2023530843A JP 2023530843 A JP2023530843 A JP 2023530843A JP 2023550485 A5 JP2023550485 A5 JP 2023550485A5
Authority
JP
Japan
Prior art keywords
nucleotides
dsrna
antisense
positions
sense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023530843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550485A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/060356 external-priority patent/WO2022109398A1/en
Publication of JP2023550485A publication Critical patent/JP2023550485A/ja
Publication of JP2023550485A5 publication Critical patent/JP2023550485A5/ja
Pending legal-status Critical Current

Links

JP2023530843A 2020-11-23 2021-11-22 Ｄｇａｔ２調節のためのオリゴヌクレオチド Pending JP2023550485A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063117005P 2020-11-23 2020-11-23
US63/117,005 2020-11-23
PCT/US2021/060356 WO2022109398A1 (en) 2020-11-23 2021-11-22 Oligonucleotides for dgat2 modulation

Publications (2)

Publication Number Publication Date
JP2023550485A JP2023550485A (ja) 2023-12-01
JP2023550485A5 true JP2023550485A5 (enExample) 2024-11-29

Family

ID=81709762

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530843A Pending JP2023550485A (ja) 2020-11-23 2021-11-22 Ｄｇａｔ２調節のためのオリゴヌクレオチド

Country Status (5)

Country Link
US (1) US20220228141A1 (enExample)
EP (1) EP4247391A4 (enExample)
JP (1) JP2023550485A (enExample)
AU (1) AU2021382621A1 (enExample)
WO (1) WO2022109398A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3929293A3 (en) 2015-04-03 2022-03-16 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
WO2017132669A1 (en) 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
WO2018031933A2 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
WO2018237245A1 (en) 2017-06-23 2018-12-27 University Of Massachusetts TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS
BR112021002440A2 (pt) 2018-08-10 2021-05-04 University Of Massachusetts oligonucleotídeos modificados visando snps
WO2020041769A1 (en) 2018-08-23 2020-02-27 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
CN113614232A (zh) 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
CA3174079A1 (en) 2020-05-26 2021-12-02 Anastasia Khvorova Synthetic oligonucleotides having regions of block and cluster modifications
EP4181932A4 (en) * 2020-07-16 2025-07-16 Univ Massachusetts CONJUGATED OLIGONUCLEOTIDES FOR SPECIFIC TISSUE DELIVERY
IL309334A (en) 2021-06-23 2024-02-01 Univ Massachusetts Anti-FLT1 optimized oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders
AU2024265748A1 (en) * 2023-05-04 2025-10-23 Argonaute RNA Limited Dual silencing
WO2024238752A1 (en) * 2023-05-17 2024-11-21 University Of Massachusetts Oligonucleotides for dgat2, fasn, opn, and nox4 modulations
WO2024245151A1 (zh) * 2023-05-26 2024-12-05 维亚臻生物技术（苏州）有限公司 一种用于代谢疾病的双链核苷酸化合物及其应用
TW202515586A (zh) * 2023-08-09 2025-04-16 大陸商北京福元醫藥股份有限公司 抑制DGAT2基因表達的siRNA、siRNA綴合物或其前藥和藥物組合物及用途
CN120035670A (zh) * 2023-08-23 2025-05-23 云合智药（苏州）生物科技有限公司 用于抑制二酰甘油-O-酰基转移酶2表达的RNAi剂及其应用
CN117257764A (zh) * 2023-09-26 2023-12-22 中国药科大学 一种脂滴衍生的核酸药物递送系统及其制备方法和应用
CN121825964A (zh) * 2023-12-26 2026-04-10 苏州吉玛基因股份有限公司 用于抑制DGAT2的siRNA及其修饰物与应用
WO2026057029A1 (zh) * 2024-09-14 2026-03-19 信达生物制药(苏州)有限公司 一种dsRNA、其应用及制备方法
WO2026130386A1 (zh) * 2024-12-17 2026-06-25 苏州时安生物技术有限公司 一种调节dgat2表达的双链rna组合物、其缀合物和药物组合物及用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1455815A4 (en) * 2001-12-19 2006-11-02 Millennium Pharm Inc MEMBERS OF THE DIACYLGLYCEROL-ACYLTRANSFERASES FAMILY 2 (DGAT2) AND USES THEREOF
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20190270995A1 (en) * 2002-11-14 2019-09-05 Thermo Fisher Scientific Inc. Methods and Compositions for Selecting siRNA of Improved Functionality
US7825235B2 (en) * 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
AU2014268529C1 (en) * 2013-05-22 2020-10-01 Alnylam Pharmaceuticals, Inc. TMPRSS6 iRNA compositions and methods of use thereof
WO2016161378A1 (en) * 2015-04-03 2016-10-06 University Of Massachusetts Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
CA2991894A1 (en) * 2015-07-10 2017-01-19 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (dgat2)
US10889813B2 (en) * 2015-09-02 2021-01-12 Alnylam Pharmaceuticals, Inc. Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
MX2019002075A (es) * 2016-08-23 2019-07-01 Dicerna Pharmaceuticals Inc Composiciones que comprenden oligonucleotidos modificados reversiblemente, y sus usos.
EP3923989A1 (en) * 2019-03-21 2021-12-22 Mitotherapeutix LLC Multivalent ligand clusters for targeted delivery of therapeutic agents
CA3164050A1 (en) * 2019-12-09 2021-06-17 Empirico Inc. Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases
TW202221120A (zh) * 2020-08-04 2022-06-01 美商黛瑟納製藥公司 用於治療代謝症候群之組成物及方法

Similar Documents

Publication Publication Date Title
JP2023522701A5 (enExample)
RU2566724C9 (ru) Композиции и способы модуляции smn2 сплайсинга у субъекта
JP6472087B2 (ja) 治療用オリゴヌクレオチドを送達するための二本鎖剤
JP6752151B2 (ja) 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー
JP2022528487A5 (enExample)
JP2023534951A5 (enExample)
JP2023518268A5 (enExample)
EP4038191A1 (en) Chemical modifications of small interfering rna with minimal fluorine content
JP2023538283A (ja) 代謝症候群の治療のための組成物及び方法
US20240401059A1 (en) Compositions and methods for modulating pnpla3 expression
CN116802295A (zh) 用于抑制中枢神经系统中的基因表达的组合物和方法
US20200138847A1 (en) Myostatin irna compositions and methods of use thereof
WO2023208109A9 (zh) 用于抑制HSD17B13表达的siRNA、其缀合物和药物组合物及其用途
CN119768186A (zh) 用于向cns组织递送治疗剂的脂质缀合物
JP2026514403A (ja) オリゴヌクレオチド送達担体およびその使用方法
CA3235941A1 (en) Compositions and methods for modulating apoc3 expression
CA3269248A1 (en) COMPOSITIONS AND METHODS OF TREATMENT FOR NEUROLOGICAL DISORDERS
EP4426839A1 (en) Lipid conjugation for targeting astrocytes of the central nervous system
WO2023081822A1 (en) Lipid conjugation for targeting oligodendrocytes of the central nervous system
WO2022184852A1 (en) Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell
JP2024518564A (ja) 中枢神経系のニューロンを標的とするための脂質コンジュゲーション
JP7536187B2 (ja) 核内受容体サブファミリー１グループｈメンバー３（ｎｒ１ｈ３）発現を阻害するための組成物および方法
EP4678747A2 (en) Double-stranded rnai agents for targeting and regulating hbv gene expression, and a use thereof
WO2026037284A1 (en) Modified dsrna molecules
JP2026509929A (ja) 改善された遺伝子サイレンシングのための組成物及び方法